About Solid Biosciences Inc.
https://www.solidbio.comSolid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy.
CEO
Alexander G. Cumbo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-10-28 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 64
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Citigroup
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:11.83M
Value:$68.75M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:7.91M
Value:$45.97M
SIREN, L.L.C.
Shares:7.42M
Value:$43.09M
Summary
Showing Top 3 of 139
About Solid Biosciences Inc.
https://www.solidbio.comSolid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $48.06M ▲ | $-45.78M ▼ | 0% | $-0.48 ▼ | $-45.4M ▼ |
| Q2-2025 | $0 | $41.31M ▲ | $-39.48M ▼ | 0% | $-0.42 ▲ | $-39.03M ▼ |
| Q1-2025 | $0 | $39.65M ▼ | $-39.28M ▲ | 0% | $-0.59 ▲ | $-38.81M ▲ |
| Q4-2024 | $0 | $39.9M ▲ | $-42.6M ▼ | 0% | $-0.8 ▼ | $-42.03M ▼ |
| Q3-2024 | $0 | $35.18M | $-32.73M | 0% | $-0.79 | $-32.24M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $236.14M ▼ | $273.91M ▼ | $55.97M ▲ | $217.95M ▼ |
| Q2-2025 | $268.11M ▼ | $308.29M ▼ | $50M ▲ | $258.29M ▼ |
| Q1-2025 | $306.92M ▲ | $343.9M ▲ | $49.44M ▼ | $294.46M ▲ |
| Q4-2024 | $148.92M ▼ | $188.66M ▼ | $51.42M ▲ | $137.25M ▼ |
| Q3-2024 | $171.12M | $211.83M | $44.8M | $167.02M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-45.78M ▼ | $-33.47M ▲ | $-45.27M ▼ | $1.18M ▲ | $-77.57M ▼ | $-33.56M ▲ |
| Q2-2025 | $-39.48M ▼ | $-37.41M ▼ | $-32.73M ▼ | $-1.6M ▼ | $-71.75M ▼ | $-37.79M ▼ |
| Q1-2025 | $-39.28M ▲ | $-31.85M ▼ | $-27.46M ▼ | $189.73M ▲ | $130.41M ▲ | $-31.98M ▼ |
| Q4-2024 | $-42.6M ▼ | $-29.64M ▼ | $38.57M ▲ | $6.94M ▲ | $15.86M ▲ | $-29.85M ▼ |
| Q3-2024 | $-32.73M | $-23.71M | $-10.99M | $3.26M | $-31.44M | $-23.72M |
CEO
Alexander G. Cumbo
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-10-28 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 64
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Citigroup
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Wedbush
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
PERCEPTIVE ADVISORS LLC
Shares:11.83M
Value:$68.75M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC
Shares:7.91M
Value:$45.97M
SIREN, L.L.C.
Shares:7.42M
Value:$43.09M
Summary
Showing Top 3 of 139